Valneva/$VALN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Ticker
$VALN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
713
ISIN
US92025Y1038
Website
Valneva Metrics
BasicAdvanced
$550M
-
-$0.63
1.10
-
Price and volume
Market cap
$550M
Beta
1.1
52-week high
$8.20
52-week low
$5.43
Average daily volume
12K
Financial strength
Current ratio
2.703
Quick ratio
1.756
Long term debt to equity
107.697
Total debt to equity
120.481
Interest coverage (TTM)
-6.60%
Profitability
EBITDA (TTM)
-157.759
Gross margin (TTM)
5.74%
Net profit margin (TTM)
-43.21%
Operating margin (TTM)
-81.28%
Effective tax rate (TTM)
-2.85%
Revenue per employee (TTM)
$302,070
Management effectiveness
Return on assets (TTM)
-19.19%
Return on equity (TTM)
-44.11%
Valuation
Price to revenue (TTM)
4.449
Price to book
2.44
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-13.723
Free cash flow yield (TTM)
-7.29%
Free cash flow per share (TTM)
-47.00%
Growth
Revenue change (TTM)
21.64%
Earnings per share change (TTM)
206.84%
3-year revenue growth (CAGR)
-18.74%
10-year revenue growth (CAGR)
12.99%
3-year earnings per share growth (CAGR)
-8.59%
10-year earnings per share growth (CAGR)
12.84%
Bulls say / Bears say
The European Medicines Agency (EMA) has lifted the temporary restriction on Valneva's chikungunya vaccine, Ixchiq, for adults aged 65 and over, potentially expanding its market reach. (reuters.com)
Valneva has entered into an exclusive vaccine marketing and distribution agreement for Germany with CSL Seqirus, enhancing its commercial footprint in a key European market. (stockanalysis.com)
Analysts have set an average 12-month price target of $15.33 for Valneva's stock, indicating a potential upside of over 155% from its current price. (stockanalysis.com)
Valneva reported a net loss of $86.89 million over the last 12 months, reflecting ongoing financial challenges. (stockanalysis.com)
The company's free cash flow stands at -$67.54 million, indicating potential liquidity concerns. (stockanalysis.com)
Valneva's chikungunya vaccine, Ixchiq, faced temporary restrictions in the UK for individuals aged 65 and over due to safety concerns, which could impact public perception and sales. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Valneva News
AllArticlesVideos
Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
GlobeNewsWire·5 days ago
Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults
Reuters·5 days ago
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Valneva stock?
Valneva (VALN) has a market cap of $550M as of July 16, 2025.
What is the P/E ratio for Valneva stock?
The price to earnings (P/E) ratio for Valneva (VALN) stock is 0 as of July 16, 2025.
Does Valneva stock pay dividends?
No, Valneva (VALN) stock does not pay dividends to its shareholders as of July 16, 2025.
When is the next Valneva dividend payment date?
Valneva (VALN) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva?
Valneva (VALN) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.